Publikation

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.

Wissenschaftlicher Artikel/Review - 15.10.2024

Bereiche
PubMed
DOI
Kontakt

Zitation
Schmid S, Holer L, Gysel K, Koster K, Rothschild S, Boos L, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur W, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti L. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. JTO Clin Res Rep 2024; 5:100735.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
JTO Clin Res Rep 2024; 5
Veröffentlichungsdatum
15.10.2024
eISSN (Online)
2666-3643
Seiten
100735
Kurzbeschreibung/Zielsetzung

On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are often considered for second or further-line (2L+) ipi-nivo on the basis of MAPS2 results. Here we report on real-world survival and safety outcomes of ipi-nivo for patients with MPM in Switzerland.